Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 138 participants.

Also called NCT01173718

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 138 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01173718
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01173718. Allocation not applicable; no masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2012-09 (actual). Results posted on 2013-07-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access
Acronym
ACUSEAL
Condition
End Stage Renal Disease
Intervention (Device)
GORE® ACUSEAL Vascular Graft
Lead sponsor
W.L.Gore & Associates (class: industry)

Record details

Record id
cardio:ct-nct01173718
Content hash
8b04173d555150b03fbe5c9d2ca802ddb106715e1d99601ee9b56e2b5db773e0